Work

Supplementary Figure S2 from First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20+ Non-Hodgkin Lymphomas

Year: 2023

Type: supplementary-materials

Abstract: Immune cell fractions derived from flow cytometry were highly concordant with those derived from RNA-Seq deconvolution in baseline blood samples from patients with follicular lymphoma. Pearson correlations were computed for each immune subset. Solid lines were fitted using linear regression.

DOI: 10.1158/1078-0432.22478288

Authors: Ajay K. Gopal, Ronald Levy, Roch Houot, Sandip P. Patel, Leslie Popplewell, Caron Jacobson, Xinmeng J. Mu, Shibing Deng, Keith A. Ching, Ying Chen, Craig B. Davis, Bo Huang, Kolette D. Fly, Aron Thall, Adrian Woolfson, Nancy L. Bartlett

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361889138

Cites:

Cited by:

Related to: 10